PreludeDx Appoints Chris Emery, VP of Strategic Marketing and Business Development

LAGUNA HILLS, Calif., Feb. 8, 2024 /PRNewswire/ — Prelude Corporation (PreludeDx), a leader in molecular diagnostics and precision medicine for early-stage breast cancer, now declared the appointment of Chris Emery to the freshly produced posture of VP of Strategic Promoting and Small business Enhancement. This position is a strategic addition to the leadership team as PreludeDx expands market adoption of its ductal carcinoma in situ (DCIS) risk evaluation check and proceeds enhancement of its molecular screening portfolio into early-stage invasive breast cancer.

“We go on to increase our products portfolio of early-phase breast cancer molecular diagnostics and accelerate adoption of our DCISionRT test among the clinicians and people for shared client choice building and enhanced outcomes,” said Dan Forche, President and CEO of PreludeDx. “With his intensive knowledge in healthcare and particularly molecular diagnostics, I am happy to welcome Chris to PreludeDx’s management crew. In this freshly designed position, Chris will concentrate on bringing our future precision drugs checks for early-stage breast most cancers to current market and discover business growth possibilities which will aid to extend the Prelude business and solution portfolio.”

Chris delivers much more than 25 years of practical experience in healthcare throughout laboratory expert services, medical machine and biopharmaceutical companies, with senior leadership roles in marketing and advertising, income and small business growth in the cancer diagnostics market. He joins PreludeDx from HALO Precision Diagnostics exactly where he served as the Main Organization Officer – Molecular Diagnostics. He was responsible for encouraging HALO create out its scientific laboratory in get to integrate breast cancer-targeted precision diagnostic tests with radiology products and services to much better serve doctors and patients in the local community health care environment. Earlier, Chris served in several leadership roles with Menarini, Abbott, Novartis and LabCorp, in which he

Read More